A proposed model for DDAb binding to an epitope on a platelet GP. The drug (oval symbol) has elements that bind to the charged and hydrophobic (H) domains on the glycoprotein epitope and the antibody's complementarity-determining region (CDR). See the original figure in the article beginning on page 922; adapted from the original by Frank Forney.